Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANGOCIN Anti-Infekt N versus placebo in acute uncomplicated rhinosinusitis
2017-002081-40Phase 4Completed
- Sponsor
- Repha
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in acute rhinosinusitis (ARS) comparing ANGOCIN Anti-Infekt N with Placebo (2 arms). Primary endpoint: Difference in mean rhinosinusitis symptom scores (MRSSinv/MRSSpat) over treatment phase. Started Jul 2017; status: completed.
02
Drugs
Angocin Anti-Infekt N
03
Conditions
acute rhinosinusitis (ARS)
Beyond the preview
Go deeper on 2017-002081-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002081-40.